![](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/05\/mycoplasma-testing-market-1-.jpg\" "\\"Mycoplasma-Testing-Market")
<\/b><\/p>\n
Get a Sample Report of Mycoplasma Testing Market@\u00a0https:\/\/www.snsinsider.com\/sample-request\/5761<\/a><\/b><\/p>\n In the United States, the market demonstrated solid momentum, accounting for USD 322.13 million in revenue in 2023. It is expected to grow at a 13.37% CAGR over the forecast period. This strong performance is supported by stringent FDA regulations on microbiological testing, rising investment in next-generation biologics, and the expanding role of contract manufacturing organizations (CMOs). With a robust pharmaceutical pipeline and proactive measures to minimize contamination risks and avoid costly product recalls, the U.S. continues to be a key driver of global market growth.<\/p>\n A main driver of the mycoplasma testing market is the growing use of biologics in therapeutic development, especially in oncology and immunology. These treatments demand aseptic manufacturing settings, so contamination detection is both operationally and regulatory necessary. Mycoplasma testing is a required quality control step in all human biological products according to the U.S. FDA’s Biologics Guidance (2023), which has driven demand for dependable, quick, and cost-effective testing tools.<\/p>\n Key Mycoplasma Testing Companies Profiled in the Report<\/b><\/p>\n Mycoplasma Testing Market Report Scope<\/b><\/p>\n Segment Insights<\/b><\/p>\n By Product<\/b><\/p>\n The Kits & Reagents segment is dominant in 2023 with a 52.33% share in the global market. For the quick, dependable, and simple solutions these products provide for identifying Mycoplasma contamination in cell cultures and biological samples, the growing inclination for commercially accessible ready-to-use kits has drastically cut the time and expenses related to regular testing. <\/p>\n Because of strict regulatory standards and the increased focus on contamination control in GMP-compliant facilities, biopharmaceutical producers depend more and more on reagent kits for both internal and outside testing. Furthermore, driving the expansion of the segment is the great need for research reagents in clinical and academic research establishments. Expected to keep their supremacy over the forecast period are technological breakthroughs, including lyophilized reagents, multiplexing kits, and PCR-enhanced kits.<\/p>\n By Technology<\/b><\/p>\n With a 34.12% share in 2023, the PCR (Polymerase Chain Reaction) segment dominated the market because of its great sensitivity, specificity, and short turnaround time. The gold standard in many QC processes, since PCR-based detection enables quick identification of Mycoplasma DNA even at low quantities.<\/p>\n Large-scale pharmaceutical manufacture and clinical research labs, as well as other high-throughput testing environments, find the method perfect for automation and real-time monitoring. Further predicted to enhance the adoption rate by enhancing quantitative detection capabilities and lowering false positives are innovations in digital PCR (dPCR) and multiplex PCR. PCR-based technologies are expected to remain fundamental in quality assurance in the pharmaceutical and biotechnology sectors as regulatory authorities suggest molecular detection more and more.<\/p>\n By End Use<\/b><\/p>\n With a 36.12% share in 2023, Pharmaceutical & Biotechnology Companies dominated the market. These companies rely on aseptic manufacturing settings and rigorous adherence to regulatory norms, so they are the main users of mycoplex testing. The increasing pipeline of biologics and biosimilars supports the segment’s growth and calls for strict quality control at every manufacturing level.<\/p>\n These firms are substantially investing in upstream and downstream contamination testing and integrating automated mycoplasma detection systems in their manufacturing pipelines as global acceptance of cell and gene treatments rises. Moreover, the move toward individualized medicine and the application of new biologics such as monoclonal antibodies and CAR-T treatments has increased the demand for strong, quick, validated microbial testing approaches.<\/p>\n For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ https:\/\/www.snsinsider.com\/request-analyst\/5761<\/a><\/b><\/p>\n Mycoplasma Testing Market Segmentation<\/b><\/p>\n By Product <\/b><\/p>\n By Technology<\/b><\/p>\n By Application<\/b><\/p>\n By End-use\u00a0\u00a0\u00a0 <\/b><\/p>\n Regional Analysis<\/b><\/p>\n North America held a 40.25% share in the global mycoplasma testing market in 2023, driven by major biopharma companies, high healthcare expenditure, and a strong regulatory framework. Regional supremacy has been strengthened by the U.S. FDA’s demand for mycoplasma screening prior to product introduction and significant funding in cell therapy manufacturing facilities. Moreover, research and development money from companies like the NIH and BARDA has inspired creativity in microbial testing techniques.<\/p>\n Expanding biopharmaceutical R&D in nations such as China, India, South Korea, and Japan would help the Asia Pacific region to have the quickest CAGR over the projection period. Government programs such as India’s Biotechnology Industry Research Assistance Council (BIRAC) and China’s 14th Five-Year Plan are giving financial support and incentives to improve biologics manufacturing capability. These advances have raised regional demand for technologies for pollution detection and control.<\/p>\n Buy a Single-User PDF of Mycoplasma Testing Market Analysis & Outlook Report 2024-2032@\u00a0https:\/\/www.snsinsider.com\/checkout\/5761<\/a><\/b><\/p>\n Table of Contents \u2013 Major Key Points<\/b><\/p>\n 1. Introduction<\/p>\n 2. Executive Summary<\/p>\n 3. Research Methodology<\/p>\n 4. Market Dynamics Impact Analysis<\/p>\n 5. Statistical Insights and Trends Reporting<\/p>\n 5.1 Contamination Incidence and Prevalence (2023)<\/p>\n 5.2 Mycoplasma Testing Trends (2023), by Region<\/p>\n 5.3 Testing Volume, by Region (2020-2032)<\/p>\n 5.4 Healthcare & Biopharma Spending on Mycoplasma Testing, by Region (2023)<\/p>\n 6. Competitive Landscape<\/p>\n 7. Mycoplasma Testing Market by Product<\/p>\n 8. Mycoplasma Testing Market by Technology<\/p>\n 9. Mycoplasma Testing Market by Application<\/p>\n 10. Mycoplasma Testing Market by End-use\u00a0\u00a0\u00a0 <\/p>\n 11. Regional Analysis<\/p>\n 12. Company Profiles<\/p>\n 13. Use Cases and Best Practices<\/p>\n 14. Conclusion<\/p>\n Related Reports:<\/b><\/p>\n Cell Therapy Market Report<\/a><\/p>\n Biologics Market Analysis<\/a><\/p>\n Pharmaceutical Sterility Testing Market<\/a><\/p>\n\n
\n Report Attributes<\/b><\/td>\n Details<\/b><\/td>\n<\/tr>\n \n Market Size in 2023<\/td>\n US$ 941.56 million<\/td>\n<\/tr>\n \n Market Size by 2032<\/td>\n US$ 2943.09 million<\/td>\n<\/tr>\n \n CAGR<\/td>\n CAGR of 13.53% From 2024 to 2032<\/td>\n<\/tr>\n \n Base Year<\/td>\n 2023<\/td>\n<\/tr>\n \n Forecast Period<\/td>\n 2024-2032<\/td>\n<\/tr>\n \n Historical Data<\/td>\n 2020-2022<\/td>\n<\/tr>\n \n Key Regional Coverage<\/td>\n North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America)<\/td>\n<\/tr>\n \n
\n
\n
\n
\n
![](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/05\/werfegeryr5s.jpg\" "\\"werfegeryr5s.jpg\\"")
<\/b><\/p>\n
![\"\"](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/05\/SNS-Insider-pvt-ltd.png\")
<\/p>\n","protected":false},"excerpt":{"rendered":"Austin, May 01, 2025 (GLOBE NEWSWIRE) — Mycoplasma Testing Market Size & Growth Analysis: According to SNS Insider,…\n","protected":false},"author":2,"featured_media":6233,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3091],"tags":[33436,51,2441,33435,33434,33432,33433,3517,16,15],"class_list":{"0":"post-65293","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-biologics-testing","9":"tag-business","10":"tag-markets","11":"tag-mycoplasma-detection","12":"tag-mycoplasma-testing-industry","13":"tag-mycoplasma-testing-market","14":"tag-mycoplasma-testing-market-size","15":"tag-sns-insider-pvt-ltd","16":"tag-uk","17":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114431841099058674","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/65293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=65293"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/65293\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/6233"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=65293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=65293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=65293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}